Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by You, J.-Y.
Right arrow Articles by Chiou, T.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by You, J.-Y.
Right arrow Articles by Chiou, T.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:618-625, 2004
© 2004 European Society for Medical Oncology

Original Paper

Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan

Received 1 December 2003; accepted 23 December 2003

Background:

To clarify the role of intention to treat for patients with localized nasal natural killer (NK)/T-cell lymphoma, and to determine the prognostic factors for these patients.

Patients and methods:

We conducted a retrospective review of 46 patients with localized nasal NK/T-cell lymphomas treated at a single institute between January 1988 and July 2002.

Results:

The type of intended treatment was a significant factor for overall survival (OS) (5-year OS: RT versus CT = 83.3% versus 28.6%, P = 0.0269) or failure-free survival (FFS) (5-year FFS: RT versus CT = 83.3% versus 27.1%, P = 0.0247). In the intended chemotherapy group, salvage with radiotherapy was superior to chemotherapy alone for OS (5-year OS: 42.2% versus 20.0%, P = 0.0252) or FFS (5-year FFS: 41.0% versus 20.0%, P = 0.0352). On multivariate analysis, both N stage and serum lactate hehydrogenase level were independent factors for OS and FFS. No radiotherapy was an independent adverse factor for OS; advanced T stage and more than one extranodal involvement were independent adverse factors for FFS.

Conclusions:

Patients with localized nasal NK/T-cell lymphomas were better managed with radiotherapy as front-line therapy. The advantage of radiotherapy persisted even as palliative therapy after chemotherapy.

J.-Y. You1, K.-H. Chi2, M.-H. Yang1, C.-C. Chen1, C.-H. Ho1, W.-K. Chau1, H.-C. Hsu1, J.-P. Gau1, C.-H. Tzeng1, J.-H. Liu1, P.-M. Chen1 and T.-J. Chiou1,*

1 Department of Medicine and 2 Cancer Center, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan

Key words: chemotherapy, combined modality, intent to treat, International Prognostic Index (IPI), nasal NK/T-cell lymphoma, radiotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
W.-y. Au, D. D. Weisenburger, T. Intragumtornchai, S. Nakamura, W.-S. Kim, I. Sng, J. Vose, J. O. Armitage, R. Liang, and for the International Peripheral T-Cell Lymphoma P
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Blood, April 23, 2009; 113(17): 3931 - 3937.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-X. Li, Q.-F. Liu, H. Fang, S.-N. Qi, H. Wang, W.-H. Wang, Y.-W. Song, J. Lu, J. Jin, S.-L. Wang, et al.
Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma
Clin. Cancer Res., April 15, 2009; 15(8): 2905 - 2912.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B.-S. Kim, D.-W. Kim, S.-A. Im, C. W. Kim, T.-Y. Kim, S.-S. Yoon, D. S. Heo, Y.-J. Bang, S. Park, B. K. Kim, et al.
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
Ann. Onc., January 1, 2009; 20(1): 121 - 128.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-X. Li, H. Fang, Q.-F. Liu, J. Lu, S.-N. Qi, H. Wang, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, et al.
Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring
Blood, October 15, 2008; 112(8): 3057 - 3064.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. M. Kim, S. -Y. Lee, Y. K. Jeon, B. -Y. Ryoo, G. J. Cho, Y. S. Hong, H. J. Kim, S.-Y. Kim, C. S. Kim, S. Kim, et al.
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group
Ann. Onc., August 1, 2008; 19(8): 1477 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. J. Savage
Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas
Hematology, January 1, 2008; 2008(1): 280 - 288.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Rodriguez-Antona, S. Leskela, M. Zajac, M. Cuadros, J. Alves, M. V. Moneo, C. Martin, J. C. Cigudosa, A. Carnero, M. Robledo, et al.
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas
Blood, November 1, 2007; 110(9): 3345 - 3351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Lee, C. Suh, J. Huh, H. J. Jun, K. Kim, C. Jung, K. Park, Y. H. Park, Y. H. Ko, and W. S. Kim
Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type
Clin. Cancer Res., June 1, 2007; 13(11): 3250 - 3254.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al.
Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Blood, March 1, 2007; 109(5): 2183 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y.-X. Li, B. Yao, and J. Jin
In Reply:
J. Clin. Oncol., June 10, 2006; 24(17): 2685 - 2686.
[Full Text] [PDF]

Home page
 Ann OncolHome page
L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, et al.
NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey
Ann. Onc., May 1, 2006; 17(5): 794 - 800.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al.
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study
J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y.-X. Li, B. Yao, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, S.-L. Wang, X.-F. Liu, L.-Q. Zhou, X.-H. He, et al.
Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma
J. Clin. Oncol., January 1, 2006; 24(1): 181 - 189.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al.
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type
Blood, December 1, 2005; 106(12): 3785 - 3790.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. J. Savage
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
Hematology, January 1, 2005; 2005(1): 267 - 277.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.